David Veitch made president of Savient Europe
This article was originally published in Scrip
Biopharmaceutical company Savient Pharmaceuticals has hired David Veitch as president of its European operations, reporting to John Johnson, the company's CEO and president. Mr Veitch will be responsible for leading the European launch of Krystexxa (pegloticase), Savient's gout treatment, pending approval. Mr Veitch most recently served as senior vice-president of European marketing & brand commercialisation at Bristol-Myers Squibb.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.